. 3 VRSA have also been found recently in the USA (where they are designated vancomycin-intermediate S. aureus (VISA) strains 5, 6 ). The frequency of VRSA in Japan is still low: Mu50 was the only VRSA strain found among 1049 MRSA isolates in Japan. However, hetero-VRSA stains are found in 9.3% of MRSA isolates in Japanese university hospitals, 3 and it is important to explore the We have previously reported methicillin-resistant Staphylococcus aureus clinical strains, Mu50 and Mu3, representing two categories of vancomycin resistance: Mu50 representing vancomycin-resistant S. aureus (VRSA) with MICs ≥ 8 mg/L, and Mu3 representing hetero-VRSA with MICs ≤ 4 mg/L using standard MIC determination methods. The mechanisms of vancomycin resistance in these strains were investigated. These strains did not carry the enterococcal vancomycin-resistance genes, vanA, vanB, or vanC1-3, as tested by PCR using specific primers. However, both strains produced three to five times the amount of penicillinbinding proteins (PBPs) 2 and 2 when compared with vancomycin-susceptible S. aureus control strains with or without methicillin resistance; the amounts of PBP2 produced in Mu3 and Mu50 were comparable to those in the vancomycin-resistant S. aureus mutant strains selected in vitro. Incorporation of 14 C-labelled N-acetyl-glucosamine into the cell was three to 20 times increased in Mu50 and Mu3, and release of the radioactive cell wall material was increased in Mu3 (and also in Mu50, though to a lesser extent), compared with control strains. The amounts of intracellular murein monomer precursor in these strains were three to eight times greater than those found in control strains. Transmission electron microscopy showed a doubling in the cell wall thickness in Mu50 compared with the control strains. Mu3 did not show obvious cell wall thickening. These data indicate that activated synthesis and an increased rate of cell wall turnover are common features of Mu3 and Mu50 and may be the prerequisite for the expression of vancomycin resistance in S. aureus. resistance mechanism of VRSA and hetero-VRSA in order to implement measures to prevent further emergence and limit dissemination of such strains.
Before the discovery of VRSA, vancomycin resistance had been reported in clinical strains of coagulase-negative staphylococci [7] [8] [9] and in mutant S. aureus strains selected in vitro. 10, 11 Shlaes et al. 12 had reported increased production of PBP2 in an S. aureus clinical strain with resistance to teicoplanin. Moreira et al. 13 observed increased production of PBP2 in in-vitro-selected vancomycin-resistant mutant S. aureus strains. They also showed by transmission electron microscopy that these strains have characteristically thickened cell walls. 10 In this study, we examined the first clinical isolate of VRSA and hetero-VRSA strains in the light of the previously reported characteristics of glycopeptide-resistant S. aureus strains.
Materials and methods

Bacterial strains
VRSA strains Mu50 and Mu45 (vancomycin MIC, 8 mg/L) and hetero-VRSA strain Mu3 (MIC, 3 mg/L) have been described previously. 2, 3 Mu27 is another isolate of hetero-VRSA from Juntendo University. Mu3m
-is a derivative of Mu3 which has lost the mecA gene by spontaneous deletion during storage.
14 Strain H1, a vancomycinsusceptible MRSA with a vancomycin MIC of 2 mg/L, and FDA209P, a vancomycin-and methicillin-susceptible S. aureus type strain with a vancomycin MIC of 1 mg/L, have also been described previously.
3 MRSA strain LR5P-1 (vancomycin MIC, 2 mg/L) is a derivative of N315LR5 from which the penicillinase has been eliminated and the mecI gene partially deleted.
14 Isogenic sets of S. aureus strains, 1714 and 1714s, 1715 and 1715w, and 523 and 523k, with and without vancomycin resistance, respectively, have been described previously. 10, 13, 15 N315P, a pre-MRSA strain (with an intact mecI gene, and susceptible to methicillin (MIC 4 mg/L)), has been described previously.
16 N315P(pYPBP2) and N315P(pYPBP2 ) are transformants of N315 with plasmids pYPBP2 and pYPBP2 , respectively (see below for a description of the plasmids). BB270 is a derivative of NCTC8325 transduced with the mec determinant, and has been described previously. 17 
Construction of recombinant plasmids
A DNA fragment containing the entire PBP2 gene was obtained by PCR amplification with genomic DNA of N315 as a template and using synthetic oligonucleotide primers (5 -AAAAGGATCCATATTCCTTATCAGT-ATCAACC-3 and 5 -TTTTGGATCCGGTTTCTACT-AATATAGCAATAGC-3 ; introduced BamHI sites are underlined). The DNA fragment containing the entire PBP2 gene (mecA) was amplified as above using synthetic oligonucleotide primers (5 -TTTTGGATCCATATCG-TGAGCAATGAACTG-3 and 5 -AAAAGGATCCA-TCGTTACGGATTGCTTC-3 ). Amplified DNA fragments were cleaved with BamHI and ligated into the unique BamHI site of a vector plasmid pYT3 to obtain recombinant plasmids pPBP2 and pPBP2 . Plasmid pYT3 is a derivative of plasmid pUC119 containing a 4.0 kb EcoRI DNA fragment of plasmid pLTV1 18 including the S. aureus replication origin of plasmid pLE194Ts 19 at the EcoRI site and a 1.6 kb PstI-EcoRI DNA fragment (flushended by the Klenow fragment of DNA polymerase I) of pHY300PLK plasmid 20 containing a tetL gene at the SmaI site. The recombinant plasmids were introduced into N315P by electroporation as described previously. 16 
Antibiotic susceptibility tests
Population analysis was performed as described previously. 3 Vancomycin MIC determination was performed on brain heart infusion (BHI) agar plates with 1 mg/L increments of drug concentration as described previously. 3 Methicillin MICs were determined on Mueller-Hinton agar plates with standard two-fold increments of antibiotic concentration as described previously. 21 Incorporation of 14 
C-labelled N-acetylglucosamine into cells in the resting medium
The test organisms were incubated at 37°C for 18 h in trypticase soy broth (TSB; BBL, Microbiology Systems, Cockeysville, MD, USA). The culture was diluted 20-fold with fresh pre-warmed TSB and further cultivated until an OD 578 of 0.7 was achieved using a U-3200 spectrophotometer (Hitachi Inc., Tokyo, Japan). The cells were then pelleted from the 4 mL portion of the culture by centrifugation at 12,000g for 10 min. The cell pellet was washed once with resting medium and resuspended in 4 mL of the resting medium. 22 The cell suspension was added to 8 L of 14 C-labelled N-acetylglucosamine (1.85 MBq/mL; Amersham, Arlington Heights, IL, USA) and 40 L of cold N-acetylglucosamine (Sigma Chemical Co., St Louis, MO, USA) to give a final concentration of 6.4 mg/L, then incubated at 37°C with gentle shaking. After 5, 15, 30, 60 or 120 min of incubation, a 0.5 mL portion of the cell suspension was taken and transferred into a microcentrifuge tube containing 0.5 mL of 0.1% sodium dodecylsulphate (SDS). After centrifugation at 12,000g for 3 min, the supernatant was discarded. The cell pellet was washed once with distilled water and resuspended in 0.5 mL of distilled water. The cell suspension was then mixed with 5 mL of AQUA SOL2 (Packard Inc., Meriden, IL, USA) and the radioactivity counted using an LS3801 liquid scintillation counter (Beckman Instruments Inc., Palo Alto, CA, USA).
Release of 14 
C-labelled N-acetylglucosamine into the culture medium
Four millilitres of an OD 578 0.7 culture, prepared as described above, was added to 8 L of 14 C-labelled Nacetylglucosamine, and incubated with shaking at 37°C for 90 min. The cells were pelleted by centrifugation at 12,000g for 3 min, followed by washing twice with prewarmed TSB. The cells were then resuspended in 4 mL of pre-warmed TSB including 100 mg/L of cold Nacetylglucosamine, and incubated at 37°C with gentle shaking. After 5, 15, 30, 60 and 120 min, a 0.5 mL sample of the culture was transferred into a microcentrifuge tube. After centrifugation at 12,000g for 3 min, the radioactivity in the supernatant was determined as described above.
PCR detection of van genes
Organisms were examined for the presence of vanA, vanB, vanC1 and vanC2/C3 genes using the procedures described by Clark et al. 23 The vanC2/C3 primers were primer vanC2-1 (5 -CGGGGAAGATGGCAGTAT-3 ) and primer vanC2-2 (5 -CGCAGGGACGGTGATTTT-3 ). Briefly, a loopful of bacterial cells taken from a blood agar plate incubated overnight was added to 23 L of chilled PCR reaction mixture containing 10 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.2 mM deoxynucleotide triphosphates (dATP, dCTP, dGTP and dTTP), 0.5 mM of each primer, and 2.5 U of Taq DNA polymerase. A Perkin-Elmer (Norwalk, CT, USA) Cetus model 9600 DNA thermocycler was programmed as follows: 10 min at 95°C; 30 cycles of 30 s at 94°C, 30 s at 58°C, and 30 s at 72°C; and 10 min at 72°C. Samples were kept at 4°C until the products could be analysed. Sixteen-microlitre samples of the PCR products were electrophoresed through a 1.5% agarose gel for 45 min at 150 V. The gels were stained with ethidium bromide and photographed under ultraviolet light. Quality control organisms for PCR included Enterococcus faecium NJ1 (vanA), Enterococcus faecalis NJ3 (vanB), Enterococcus gallinarum NJ4 (vanC1), Enterococcus casseliflavus ATCC 25788 (vanC2) and E. faecalis ATCC 29212 (negative control).
Western blotting detection of PBPs
PBP2 was detected as described previously. 16 The methods used for detecting PBP2 and PBP1 have been described previously, 13, 15 except that rabbit antibodies specific to PBP2 and PBP1 were used in this study. The antibodies were raised against two synthetic peptides, ANEKYLVKNAQQPERGKIYDC (part of the predicted amino acid sequence of PBP1; GenBank accession number D28879) and CKTLQQNDVDNG (part of the predicted amino acid sequence of PBP2; EMBL accession number X62288). Each peptide was chemically conjugated with keyhole limpet haemocyanin in a ratio of 5:1 using m-maleimidobenzoyl-N-hydroxysuccinimide ester as cross-linker, 24 and used for immunization.
Analysis of murein monomer precursor (UDP-Nacetylmuramyl-pentapeptide)
Test organisms were incubated at 37°C for 18 h in BHI broth (BBL). The culture was then diluted 20-fold with fresh pre-warmed BHI broth, and further cultivated until an OD 578 of 0.7 was attained. A 25 mL portion of the culture was then added to 225 mL of fresh pre-warmed BHI broth in a Sakaguchi flask and further incubated at 37°C with a gyratory shaker (Bio-Shaker BR-150L; Taitec, Tokyo, Japan) until an OD 578 of 0.7 was reached. The cells were harvested by centrifugation at 10,000g for 15 min, and were washed once with distilled water. The pellet was then resuspended in 10 mL of distilled water, and the cell suspension was added into 20 mL of boiling water. The cell suspension was boiled for 20 min, then subjected to centrifugation at 100,000g for 70 min. Supernatant was taken and lyophilized. The lyophilized sample was dissolved in 2 mL of distilled water and subjected to reversed-phase HPLC using a Galliver HPLC system (Nihonbunko Inc., Tokyo, Japan 
Autolysis assay
Cells were grown to an OD 600 of 0.7 in TSB broth at 37°C, and were pelleted by centrifugation at 3700g for 5 min. The cells were washed once with saline, and resuspended in 0.01 M sodium phosphate buffer, pH 7.0 to about 0.8 at OD 600 . The cell suspension was incubated at 37°C with continuous gentle shaking. Decrease in optical density was monitored every 1 h with a Bio-Photo Recorder TN-2612 (Advantec, Osaka, Japan).
Zymographic detection of autolysis
Cells were grown to an OD 600 of 1.0 in TSB at 37°C, and were pelleted by centrifugation at 10,000g for 20 min. The cells were washed once with saline, and resuspended in 4% SDS (1 mL/g of wet cells). The cell suspension was incubated for 30 min at 25°C with gentle stirring, and the cells were pelleted by centrifugation at 30,000g for 10 min.
The supernatant was used as the crude autolysin. The crude autolysin was then dialysed against electrophoresis running buffer (0.05 M Tris-glycine pH 8.3, with 0.1% SDS) at 4°C for 18 h. Protein concentration was determined using the Dc protein assay (Bio-Rad, Hercules, CA, USA) with bovine serum albumin solutions as standards, and 1.2 g of the sample was applied to each lane of an SDS-polyacrylamide gel. The electrophoresis and visualization of autolytic activity of the autolysin were performed as described by Sugai et al. 25 Comparison of the autolytic activity displayed by the tested strains was made by densitometry using Scanalytics (CSPI, Billerica, MA, USA).
Transmission electron microscopy
Cells in logarithmic growth phase were fixed in 2% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.4, for 2 h, and treated with 1% osmium tetroxide for 2 h at 4°C. Cells were dehydrated with graded concentrations of ethanol, and embedded in EPOK812 (Ohken, Tokyo, Japan). Ultra-thin sections were stained with uranyl acetate and lead citrate, and then examined with a transmission electron microscope TEM-1200EX (Jeol, Tokyo, Japan). Figure 2 illustrates the time course of release of radioactivity into the culture supernatant from the cells of tested strains. Mu3 had an accelerated release of cell wall material into the supernatant compared with H1 and FDA209P. The release from Mu50 cells was slower than that from Mu3 cells, but faster than that from H1 and FDA209P cells.
Results
Accelerated incorporation of N-acetylglucosamine into Mu3 and Mu50 cells compared with control strains in resting medium
Accelerated release of N-acetylglucosamine from Mu3 and Mu50
Absence of van genes in Mu3 and Mu50
PCR amplification using template DNAs extracted from Mu3 and Mu50 and van-gene specific primer combinations (for vanA, vanB and vanC1-3) did not yield any DNA fragment detectable by agarose gel electrophoresis (data not shown). Figure 3 shows Western blot detection of PBPs in Mu3, Mu50 and control strains. Figure 3a shows that Mu3 and Mu50 produced much more PBP2 than vancomycinsusceptible strains LR5P-1 and FDA209P. There was not more PBP1 in Mu3 or Mu50 than in the control strains. Figure 3b shows that Mu3 and Mu50 produced more PBP2 than LR5P-1, which produces PBP2 constitutively. Since it is an MSSA strain, FDA209P does not produce PBP2 . Figure 3c shows that the amount of PBP2 produced in Mu3 was comparable to that in strain 523k, a vancomycin-resistant mutant strain which has been reported previously to produce more PBP2 than its vancomycin-susceptible parent strain 523 (lane 1, Figure  3c ). 13 Figure 3d shows that the amount of PBP2 produced by Mu50, Mu45 (VRSA) and Mu27 (hetero-VRSA) were all equivalent to those of in-vitro trained VRSA strains 1715w, 1714s and 523k.
Increased production of PBP2 and PBP2 in Mu3 and Mu50
The effect of overproduction of PBPs and loss of mecA on vancomycin resistance
In order to test which of the two PBPs, PBP2 or PBP2 , was associated with the vancomycin resistance, each PBP was overproduced by introducing the recombinant plasmids into N315P. Western blotting showed that PBP2 was overproduced in N315P(pYPBP2) (Figure 4a) , and PBP2 in N315P(pYPBP2 ) (Figure 4b ). N315P(pYPBP2) produced 6.6 times more PBP2 than N315P. N315P(pPBP2 ) produced 12.5 times more PBP2 than N315P. The population analysis shown in Figure 4c demonstrated that N315P(pYPBP2) had an elevated vancomycin resistance, although not to the level of Mu3. The vancomycin MIC for N315P(pYPBP2) was 2 mg/L, whereas MICs for N315P and Mu3 were 1 and 3 mg/L, respectively. Methicillin MIC for N315P(pYPBP2) remained the same as that of N315P (MIC, 2 mg/L). By contrast, N315P(pYPBP2 ) retained substantially the same level of vancomycin susceptibility as N315P (MIC, 1 mg/L). However, the methicillin MIC of N315P(pYPBP2 ) was raised to 64 mg/L, while that of N315P was 2 mg/L. Figure 4c also shows that the population curves for Mu3 and its mec-negative derivative strain, Mu3m -, which does not produce PBP2 and has the same level of increased PBP2 production (data not shown), were not changed appreciably. peak corresponding to the normal murein monomer precursor, UDP-N-acetylmuramyl-pentapeptide, was seen in all the tested strains (arrows). There was no peak corresponding to the murein monomer precursor with a D-lactate terminus (data not shown). Figure 6 shows the amount of murein monomer precursor in a fixed number of cells of the tested strain relative to that of FDA209P. Mu50 and Mu3 had 7.3 and 8.8 times, respectively, the amount of murein monomer precursor found in FDA209P. There was no increase in the murein monomer precursor pool in the transformant strain N315P(pYPBP2), which had greater vancomycin resistance than the parent strain N315P.
Analysis of intracellular murein monomer precursor pool in Mu3, Mu50 and control strains
Transmission electron microscopy of Mu3 and Mu50
Transmission electron microscopy showed that in Mu50 (Figure 7a 
Autolytic activity and autolysin production
Mu3 and Mu50 demonstrated greater autolytic activities than the control strains FDA209P, LR5P-1 and H1 ( Figure  8 ). Figure 9 shows a zymograph of autolytic enzymes produced by Mu3, Mu50 and the control strains. Bands of 138, 115 and 51 kDa were identified, corresponding respectively to the uncleaved ATL protein, the inter- mediately processed ATL protein, and the completely processed endo--N-acetylglucosaminidase. The autolytic activity of fully processed endo--N-acetylglucosaminidase in Mu50, as judged by analysing the zymograph by densitometry, was 1.9 times higher than that in H1, 2.6 times higher than that in FDA209P and 4.1 times higher than that in LR5P-1. Mu3 displayed activity almost equivalent to Mu50 (0.93 times that of Mu50).
Discussion
Vancomycin-resistant clinical strains, Mu50 (VRSA) and Mu3 (hetero-VRSA) had identical PFGE banding patterns and are considered to share the same clonal origin. 3 In-vitro exposure of Mu3 to vancomycin selected mutants with raised vancomycin resistance (MIC, 8 mg/L) at a frequency of 10 -6
. 3 This frequency is remarkably high in view of the previous reports on the difficulty of inducing vancomycin resistance in either S. aureus 26, 27 or coagulasenegative staphylococci. 28 Shlaes & Shlaes 26 obtained no vancomycin-resistant mutants from 5 10 10 cfu of an S. aureus clinical strain with vancomycin selection. It seems that multiple genetic changes are required for staphylococci to acquire vancomycin resistance. In view of this, it is probable that the hetero-VRSA strain Mu3 had already undergone certain genetic alterations prerequisite for expression of vancomycin resistance, so that only one more genetic change was required to achieve the level of vancomycin resistance of Mu50. Therefore, some of the features shared by Mu3 and Mu50 but not seen in vancomycin-susceptible control strains might correspond to the prerequisites for vancomycin resistance. Six such features were observed: (i) accelerated uptake of Nacetylglucosamine into the cell; (ii) accelerated release of cell wall material into the culture medium; (iii) increased cytoplasmic murein monomer precursor pool; (iv) increased production of PBP2 (and PBP2 ); (v) relatively high autolytic activity; and (vi) increased production of autolytic enzymes. These phenotypes, which could collectively be termed 'activated synthesis and turnover of cell wall', may be the prerequisite for the expression of vancomycin resistance in the Mu3-Mu50 lineage of S. aureus strains.
So far, enterococcal van genes have not been detected in glycopeptide-resistant staphylococcal clinical strains. 29 The genes were not found in Mu3 or Mu50 either. The absence of van genes was consistent with the relatively limited level of vancomycin resistance of these strains (MIC, 8 mg/L for Mu50 and 3 mg/L for Mu3) compared with those of vancomycin-resistant enterococci (MIC 128 mg/L for the VanA phenotype, and MIC 16 mg/L for the usual VanB phenotype). 29 The absence of van genes also suggests that resistance in Mu3 and Mu50 does not result from the alteration of the terminus of murein monomer precursor, i.e. D-alanyl-D-lactate substituting for D-alanyl-D-alanine. 30 In agreement with this, HPLC analysis of murein monomer precursor did not reveal a peak at the retention time corresponding to the murein monomer precursor with the D-lactate terminus.
Shlaes et al. 12 have reported increased production of PBP2 in a teicoplanin-resistant S. aureus clinical strain. Moreira et al. 13 showed that this increased production of PBP2 is correlated with vancomycin resistance. They proposed that the increased number of PBP2 molecules compete better with vancomycin for the peptidoglycan precursor, thus making the synthesis of nascent peptidoglycan synthesis less vulnerable to inhibition. 13 In the present study, Mu3 and Mu50 also exhibited increased production of PBP2, and the role of PBP2 in raising vancomycin resistance was further substantiated by experimental overproduction of PBP2 in a vancomycinsusceptible S. aureus strain. However, it is also evident that PBP2 overexpression per se is not sufficient for attaining the level of hetero-vancomycin resistance of Mu3 (Figure 4b) , which suggests that some other factor(s) are also required to attain the status of hetero-vancomycinresistant Mu3. This factor(s) may be related to the observed activation of cell wall synthesis in Mu3, more specifically, the increased N-acetylglucosamine incorporation into the cell wall and increased supply of cytoplasmic murein monomer precursor in Mu3 (and Mu50), which are lacking in the transformant strain N315P(pYPBP2) (Figure 6, and unpublished observation) .
Production of PBP2 , the PBP responsible for methicillin resistance, [31] [32] [33] was also increased significantly in Mu3 and Mu50. However, the overproduction of PBP2 did not seem to contribute to the raised expression of vancomycin resistance, since spontaneous deletion of the mecA gene, which is known to occur in MRSA strains during storage or cultivation in drug-free medium, 34 did not appreciably influence the susceptibility pattern of Mu3. In support of this, overexpression of PBP2 in N315P increased resistance to methicillin but not to vancomycin. Therefore, it seems to be PBP2 rather than PBP2 that contributes to the raised vancomycin resistance. This poses the question whether PBP2 has an additional function besides the transpeptidase function which apparently is also possessed by PBP2 . 35, 36 It is curious that production of PBP2 is increased in Mu3 and Mu50 concomitantly with PBP2, if PBP2 does not contribute to vancomycin resistance. It may be that some trans-acting signal to regulate the amounts of PBPs in S. aureus is common to PBP2 and PBP2 , and a signal causing increased production of PBP2 might result in the concomitant up-regulation of PBP2 production.
Evidently, those features common to Mu3 and Mu50 discussed above cannot make the cell express the level of vancomycin resistance of Mu50. There ought to be an additional mutation which causes the vancomycin resistance to increase from the level seen in Mu3 to that in Mu50. The observed phenotypic difference between Mu3 and Mu50 in this study were: (i) slower release of cell wall material in Mu50, and (ii) increased cell wall thickness in Mu50. Similar cell wall thickening associated with vancomycin resistance has been reported previously in the VRSA mutant strain 523k in comparison with its parent strain 523. 10 The increased cell wall thickness of Mu50 probably resulted from the observed slower release rate of the cell wall material in Mu50 compared with Mu3. Although the mechanism for this difference is unknown, since the rate of cell wall synthesis as judged by the uptake of N-acetylglucosamine was comparable between Mu3 and Mu50, delayed release of the cell wall material in Mu50 should result in the accumulation of greater amount of cell wall material in Mu50 than in Mu3. Recent comparative analysis of the mutanolysin-cleaved peptidoglycan subunits of Mu50 and Mu3 revealed a greatly increased proportion of glutamine-non-amidated peptidoglycan subunits and significantly decreased cross-linking in the peptidoglycan in Mu50 when compared with those in Mu3 (unpublished). Production of glutamine-nonamidated muropeptide in S. aureus is known to be characteristic of femC mutants with methicillin resistance. 37 A search for a femC-like genetic change in Mu50 is now under way. Although our results suggest that cell wall synthesis is activated in Mu3 and Mu50, it remains to be seen which point(s) in the cell wall synthetic pathway are involved, and whether the nature of the alteration in Mu50 differs from that in Mu3 or not. The experiments addressing these remaining questions are now in progress.
Addendum
The overproduction of PBP2 in N315P raised vancomycin resistance only slightly. But subsequent measurement of susceptibilities of N315P and N315P (pYPBP2) to teicoplanin, another clinically available glycopeptide antibiotic, showed substantial increase in the level of resistance; teicoplanin MIC values were 1 mg/L and 8 mg/L, respectively. Given the similar mode of action of the two glycopeptide antibiotics, the data further supports a contribution of overproduction of PBP2 in raised vancomycin resistance in Mu3 and Mu50.
